Epitracker Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.13M
- Investors
-
2
Epitracker General Information
Description
Developer of drug development technology designed for leveraging nature to discover safe and effective therapies that improve global health. The company's technology analyzes metabolomic, genomic, and clinical data from archived navy dolphin samples collected throughout their lifetimes, as part of their routine health care, enabling healthcare professionals to improve human and animal health.
Contact Information
Website
www.epitracker.comCorporate Office
- 2850 Womble Road
- Suite 100-600
- San Diego, CA 92106
- United States
Corporate Office
- 2850 Womble Road
- Suite 100-600
- San Diego, CA 92106
- United States
Epitracker Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 22-Jun-2023 | $1.13M | Completed | Pre-Clinical Trials | ||
| 3. Grant | 30-Dec-2019 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Jan-2018 | $3.6M | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | 29-Mar-2017 | $3.6M | $3.6M | Completed | Pre-Clinical Trials |
Epitracker Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
Epitracker Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Epitracker Patents
Epitracker Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230132955-A1 | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity | Pending | 03-Nov-2021 | ||
| EP-4426130-A1 | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity | Pending | 03-Nov-2021 | ||
| JP-2024539823-A | Pentadecanoylcarnitine for the treatment of conditions related to the quality of aging and longevity | Pending | 03-Nov-2021 | ||
| US-20230293491-A1 | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity | Pending | 03-Nov-2020 | ||
| AU-2021329909-A1 | Compositions and methods for mood enhancement | Pending | 20-Aug-2020 | A23L33/115 |
Epitracker Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Epitracker Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| United States Department of Defense | Government | |||
| CONNECT(San Diego) | Accelerator/Incubator |
Epitracker FAQs
-
When was Epitracker founded?
Epitracker was founded in 2016.
-
Where is Epitracker headquartered?
Epitracker is headquartered in San Diego, CA.
-
What is the size of Epitracker?
Epitracker has 4 total employees.
-
What industry is Epitracker in?
Epitracker’s primary industry is Drug Discovery.
-
Is Epitracker a private or public company?
Epitracker is a Private company.
-
What is Epitracker’s current revenue?
The current revenue for Epitracker is .
-
How much funding has Epitracker raised over time?
Epitracker has raised $3.6M.
-
Who are Epitracker’s investors?
United States Department of Defense and CONNECT(San Diego) have invested in Epitracker.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
